Vaccinazione contro il Virus Sinciziale Respiratorio Materno Prefusione F e Malattia Respiratoria Acuta nei Neonati.

IMPORTANCE: The bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine was licensed in the US in September 2023 to prevent RSV-associated lower respiratory tract disease (LRTD) in infants via maternal immunization. Clinical data on vaccine effectiveness are limited. OBJECTIVE: To estimate the effectiveness of maternal RSVpreF vaccination against hospitalization for RSV-associated acute respiratory illness (ARI) and LRTD among infants 90 days or younger during the first 2 postlicensure RSV seasons. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case-control study (Effectiveness of ABRYSVO Maternal Respiratory Syncytial Virus Vaccine Against RSV in Infants in Western Penns